All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
Hepatotoxicity (aspartate aminotransferase > 1000 IU/L) · people with paracetamol (acetaminophen) overdose
Cysteamine may leads to lower hepatotoxicity (aspartate aminotransferase > 1000 IU/L) compared with no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with dimercaprol (very low certainty).
1 finding from 1 review
Mean maximum alanine aminotransferase (IU/L) · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity (aspartate aminotransferase > 1000 IU/L) · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes hepatotoxicity (aspartate aminotransferase > 1000 U/L) compared with methionine (randomised trials) (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Hepatocellular carcinoma · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chronic HCV infection†‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ MTH‐68/B vaccine versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ MTH‐68/B vaccine versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (proportion) ‐ interferon‐alpha versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐alpha versus no intervention compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection
It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
Health‐related quality of life · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Liver transplantation · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Decompensated liver disease · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cirrhosis · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).
1 finding from 1 review